Versant Capital Management’s Relay Therapeutics RLAY Stock Holding History

Versant Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5K	Buy	559 +66	+13%	+$958	﹤0.01%	2215
2026 Q1	$4.91K	Hold	493	–	–	﹤0.01%	2387
2025 Q4	$4.17K	Hold	493	–	–	﹤0.01%	2315
2025 Q3	$2.57K	Hold	493	–	–	﹤0.01%	2367
2025 Q2	$1.71K	Sell	493 -965	-66%	-$2.87K	﹤0.01%	2412
2025 Q1	$3.82K	Buy	+1,458	New	+$5.71K	﹤0.01%	2124
2024 Q3	–	Sell	-309	Closed	-$2.02K	–	2069
2024 Q2	$2.02K	Buy	309 +231	+296%	+$1.58K	﹤0.01%	1510
2024 Q1	$647	Hold	78	–	–	﹤0.01%	1641
2023 Q4	$859	Buy	+78	New	+$658	﹤0.01%	1558
2023 Q3	–	Sell	-90	Closed	-$1.13K	–	2037
2023 Q2	$1.13K	Buy	+90	New	+$1.12K	﹤0.01%	1557

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Versant Capital Management's RLAY Position: Q2 2026 in Review

Versant Capital Management increased its Relay Therapeutics (RLAY) stake by 13% in Q2 2026, buying an estimated $958 and bringing the position to 559 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Versant Capital Management first reported a position in RLAY in Q2 2023 and has held it in 10 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

Versant Capital Management held 559 shares of Relay Therapeutics worth $10.5K as of Q2 2026.
Versant Capital Management bought 66 Relay Therapeutics shares in Q2 2026, an estimated $958.
Relay Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2215 holding.
Versant Capital Management first reported a position in Relay Therapeutics in Q2 2023 and has held it in 10 quarters since.
259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.